Comparative Pharmacology
Head-to-head clinical analysis: LOTENSIN versus LOTENSIN HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOTENSIN versus LOTENSIN HCT.
LOTENSIN vs LOTENSIN HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benazepril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This leads to decreased vasopressor activity, aldosterone secretion, and increased plasma renin activity.
Lotensin HCT is a combination of benazepril, an angiotensin-converting enzyme (ACE) inhibitor, and hydrochlorothiazide, a thiazide diuretic. Benazepril inhibits ACE, reducing angiotensin II formation, leading to vasodilation and decreased aldosterone secretion. Hydrochlorothiazide increases sodium and water excretion by inhibiting the sodium-chloride symporter in the distal convoluted tubule, reducing plasma volume.
10-40 mg orally once daily; initial dose 10 mg once daily; maximum 80 mg/day.
One tablet (10 mg benazepril/12.5 mg hydrochlorothiazide, 20 mg benazepril/12.5 mg hydrochlorothiazide, or 20 mg benazepril/25 mg hydrochlorothiazide) orally once daily. Dose titration: initially 10/12.5 mg, may increase to 20/12.5 mg or 20/25 mg if needed.
None Documented
None Documented
Terminal elimination half-life: 12-13 hours for benazeprilat; 0.6 hours for benazepril. Clinical context: Half-life supports once-daily dosing, extending to 22-27 hours in severe renal impairment (CrCl <30 mL/min) requiring dose adjustment.
Benazeprilat: 10-11 hours (effective half-life 22 hours in hypertension at steady state); Benazepril: 0.6 hours
Renal: ~60% unchanged in urine; Biliary/fecal: ~20% as metabolites; Total renal elimination: ~80-85% (parent drug + metabolites).
Renal: ~90% (benazeprilat, benazepril, and conjugates); Biliary/fecal: ~10%
Category C
Category C
ACE inhibitor
ACE inhibitor and diuretic combination